Contract development and manufacturing organization (CDMO) Ardena has marked a sustained period of growth with a move to expanded headquarters in Gent, Belgium.
Since 2015, the company has grown from 40 to 250 staff members and reported more than 20 percent organic growth per year, fueled by four acquisitions in the last two years, most recently Netherlands-based ChemConnection and Sweden-based Syntagon.
It now operates across six sites in Belgium, the Netherlands, Sweden, and Latvia and boasts a global reach, servicing more than 300 customers in Europe, the U.S., Japan, and Korea.
Ardena offers integrated drug development services encompassing drug substance and drug product development, clinical manufacturing, clinical logistics, full product analytical and bioanalytical support, and regulatory dossier development. The company also is a leader in nanomedicine technology.
CEO Harry Christiaens said the company is on track to reach a €35 million ($40 million) sales target for 2018 as part of a wider strategy to become a leading integrated drug development company.
“This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities,” Christiaens said. “As we move into 2019, we look forward to continued international success and carrying on with our acquisition strategy to further strengthen our service offering.”
Ardena was formed following the merging of three companies: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands.
The inauguration of the new headquarters took place October 25.